Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mu-type, kappa-type, and delta-type opioid receptors are the three principal subtypes of classical opioid receptors, all of which belong to the G protein-coupled receptor (GPCR) family. These receptors mediate the effects of endogenous opioid peptides (such as endorphins, enkephalins, and dynorphins) as well as exogenous opioid drugs by coupling primarily to Gi/o proteins, which inhibit adenylate cyclase activity and modulate ion channels to reduce neuronal excitability[1][3][6]. - The mu opioid receptor (MOR) is the main mediator of most clinically relevant opioid effects including analgesia, euphoria, respiratory depression, miosis, and physical dependence[3][6][4]. - The kappa opioid receptor (KOR) primarily modulates spinal analgesia, diuresis, and dysphoria, and has roles in mood and the perception of pain and stress[3][4][5][6]. - The delta opioid receptor (DOR) is less well-studied but is implicated in mood regulation, modulation of pain (especially under inflammatory states), and gastrointestinal function[3][4][5][6]. Each receptor type has a distinct anatomical distribution within the central and peripheral nervous system and can form functional complexes or heterodimers, which may alter their pharmacological and physiological properties[1][2][6]. For clinical relevance, these receptors are the primary therapeutic targets for opioid analgesics, substances used in pain management, and for drugs addressing opioid dependence and overdose[3][4][6]. However, their chief therapeutic challenge lies in the high risk of tolerance, dependence, and significant side effects such as respiratory depression, constipation, and abuse potential, particularly with mu receptor agonists[3][4].
Agonism, Partial agonism, Antagonism, Biased agonism (G-protein coupling, beta-arrestin pathway modulation)
17 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mu-type opioid receptor, Kappa-type opioid receptor, and Delta-type opioid receptor (MOR (mu-type opioid receptor), KOR (kappa-type opioid receptor), DOR (delta-type opioid receptor)).